164 related articles for article (PubMed ID: 29303703)
1. Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment.
Kostik MM; Isupova EA; Chikova IA; Dubko MF; Masalova VV; Snegireva LS; Kalashnikova OV; Chasnyk VG
Clin Exp Rheumatol; 2018; 36(2):335-341. PubMed ID: 29303703
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
[TBL] [Abstract][Full Text] [Related]
3. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
Bielak M; Husmann E; Weyandt N; Haas JP; Hügle B; Horneff G; Neudorf U; Lutz T; Lilienthal E; Kallinich T; Tenbrock K; Berendes R; Niehues T; Wittkowski H; Weißbarth-Riedel E; Heubner G; Oommen P; Klotsche J; Foell D; Lainka E
Pediatr Rheumatol Online J; 2018 Apr; 16(1):22. PubMed ID: 29622022
[TBL] [Abstract][Full Text] [Related]
4. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
[TBL] [Abstract][Full Text] [Related]
6. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
[TBL] [Abstract][Full Text] [Related]
8. IL-6 blockers in systemic onset juvenile idiopathic arthritis.
Barone P; Pignataro R; Garozzo MT; Leonardi S
Immunotherapy; 2016; 8(1):79-87. PubMed ID: 26642378
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
Yasuoka R; Iwata N; Abe N; Kohagura T; Nakaseko H; Shimizu M; Kawabe S
Mod Rheumatol; 2019 Mar; 29(2):324-327. PubMed ID: 29578355
[TBL] [Abstract][Full Text] [Related]
10. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
[TBL] [Abstract][Full Text] [Related]
11. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.
Wu J; Sun L; Tang X; Zheng Q; Guo L; Xu L; Li Y; Lu M
Mod Rheumatol; 2022 Oct; 32(6):1114-1121. PubMed ID: 34971386
[TBL] [Abstract][Full Text] [Related]
12. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
13. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis.
He T; Ling J; Yang J
Sci Rep; 2023 Jun; 13(1):9050. PubMed ID: 37270663
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.
Park EH; Lee EY; Shin K; Kim HA
Rheumatol Int; 2020 May; 40(5):791-798. PubMed ID: 31598752
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
Yokota S; Itoh Y; Morio T; Origasa H; Sumitomo N; Tomobe M; Tanaka K; Minota S
Ann Rheum Dis; 2016 Sep; 75(9):1654-60. PubMed ID: 26644233
[TBL] [Abstract][Full Text] [Related]
17. Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab - a real-world experience.
Aeschlimann FA; Dumaine C; Wörner A; Mouy R; Wouters C; Melki I; Uettwiller F; Job-Deslandre C; Quartier P; Bader-Meunier B
Semin Arthritis Rheum; 2020 Aug; 50(4):744-748. PubMed ID: 32526594
[TBL] [Abstract][Full Text] [Related]
18. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
Miyamae T; Yokoya S; Yamanaka H; Yokota S
Mod Rheumatol; 2014 Jul; 24(4):567-71. PubMed ID: 24252004
[TBL] [Abstract][Full Text] [Related]
19. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Machado SH; Xavier RM
Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
[TBL] [Abstract][Full Text] [Related]
20. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Likhacheva TS; Isupova EA; Glebova NI; Kuchinskaya EM; Balbotkina EV; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Semin Arthritis Rheum; 2015 Feb; 44(4):417-22. PubMed ID: 25300700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
